Fosun Pharma (02696) enters into a licensing agreement with Alvogen Korea for the drug Hanshi Zhuang

Wisdom Financial APP News, Fuhong Hanlin (02696) announced that the company entered into a license agreement with Alvogen Korea Co., Ltd. on April 25, 2025. According to the agreement, the company granted Alvogen Korea an exclusive license to commercialize Hanshuang (Suluridine) injection in South Korea.